Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: Three studies - Jenner, Peter; Könen-Bergmann, Michael; Schepers, Cornelia; Haertter, Sebastian (Clinical therapeutics, 2009)
Keywords: Adolescent; Adult; Antiparkinson Agents - administration & dosage; Antiparkinson Agents - adverse effects; Antiparkinson Agents - pharmacokinetics; Area Under Curve; Benzothiazoles - administration & dosage; Benzothiazoles - adverse effects; Benzothiazoles - pharmacokinetics; Bioavailability; Bioequivalence; Biological and medical sciences; Biological Availability; Body Mass Index; Chemistry, Pharmaceutical; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Delayed-Action Preparations; Dietary Fats; Dopamine; Drug dosages; Dyskinesia; extended release; Food-Drug Interactions; Health sciences; Humans; immediate release; Internal Medicine; Male; Medical Education; Medical sciences; Nervous system (semeiology, syndromes); Nervous system as a whole; Neurology; Parkinson's disease; Pharmacokinetics; Pharmacology. Drug treatments; pramipexole; Reproducibility of Results; steady state; Young Adult; United Kingdom--UK; Germany; steady state; Parkinson's disease; pramipexole; immediate release; extended release; Agonist; Parkinson disease; Pramipexole; Formulation; Immediate release form; Single daily dose; Degenerative disease; Human; Nervous system diseases; Healthy subject; Controlled release form; Neuroprotective agent; Antiparkinson agent; Cerebral disorder; D2 Dopamine receptor; Central nervous system disease; Dopamine agonist; Dosage form; Daily dose; Pharmacokinetics; Extrapyramidal syndrome